MARKET

GLTO

GLTO

Galecto Inc.
NASDAQ
30.00
-1.60
-5.06%
After Hours: 29.42 -0.58 -1.93% 19:34 12/16 EST
OPEN
30.40
PREV CLOSE
31.60
HIGH
32.55
LOW
28.11
VOLUME
62.02K
TURNOVER
--
52 WEEK HIGH
33.60
52 WEEK LOW
2.010
MARKET CAP
47.85M
P/E (TTM)
-2.4988
1D
5D
1M
3M
1Y
5Y
1D
Galecto Grants Stock Options to New Employee Under Inducement Plan
Reuters · 9h ago
GALECTO, INC. ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 9h ago
Weekly Report: what happened at GLTO last week (1208-1212)?
Weekly Report · 1d ago
Galecto Issues Correction to Series C Preferred Stock Designation
Reuters · 12/09 22:00
Galecto Price Target Raised to $36.00/Share From $32.00 by Guggenheim
Dow Jones · 12/08 13:44
Galecto Is Maintained at Buy by Guggenheim
Dow Jones · 12/08 13:44
Guggenheim Maintains Buy on Galecto, Raises Price Target to $36
Benzinga · 12/08 13:35
Guggenheim Keeps Their Buy Rating on Galecto (GLTO)
TipRanks · 12/08 13:17
More
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Webull offers Galecto Inc stock information, including NASDAQ: GLTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLTO stock methods without spending real money on the virtual paper trading platform.